Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gelderblom

Showing results (191-200 of 251) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 26, 2025
Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC studyE Roets, E Younger, R L Jones, et al.
Annals of Surgical Oncology|June 1, 2017
Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II StudyC Bisschop, T H van Dijk, J C Beukema, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2016
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancerD de Wit, T C Schneider, D J A R Moes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumorsM J de Jonge, C J Punt, A H Gelderblom, et al.
Acta Oncologica (Stockholm, Sweden)|November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysisA Kollár, R L Jones, S Stacchiotti, et al.
Clinical Radiology|January 23, 2021
Personalising sarcoma care using quantitative multimodality imaging for response assessmentG M Kalisvaart, J L Bloem, J V M G Bovée, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 13, 2020
Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancerR T Lugtenberg, M J Fischer, F de Jongh, et al.
ESMO Open|December 9, 2022
Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?N S IJzerman, E van Werkhoven, M Mohammadi, et al.
Gynecologic Oncology|May 22, 2016
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapyI Ray-Coquard, E Rizzo, J Y Blay, et al.
Pageof 26

Showing results (191-200 of 251) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 26, 2025
Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC studyE Roets, E Younger, R L Jones, et al.
Annals of Surgical Oncology|June 1, 2017
Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II StudyC Bisschop, T H van Dijk, J C Beukema, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2016
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancerD de Wit, T C Schneider, D J A R Moes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumorsM J de Jonge, C J Punt, A H Gelderblom, et al.
Acta Oncologica (Stockholm, Sweden)|November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysisA Kollár, R L Jones, S Stacchiotti, et al.
Clinical Radiology|January 23, 2021
Personalising sarcoma care using quantitative multimodality imaging for response assessmentG M Kalisvaart, J L Bloem, J V M G Bovée, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 13, 2020
Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancerR T Lugtenberg, M J Fischer, F de Jongh, et al.
ESMO Open|December 9, 2022
Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?N S IJzerman, E van Werkhoven, M Mohammadi, et al.
Gynecologic Oncology|May 22, 2016
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapyI Ray-Coquard, E Rizzo, J Y Blay, et al.
Pageof 26